Cel-Sci (CVM) AI Stock Analysis

• Market Cap: $43.14M
• Dividend Yield: N/A
• Average Volume (3M): 125.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: N/A
• EPS Growth: 48.68%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.36
• Shares Outstanding: 8,408,746
• 10 Day Avg. Volume: 66,836
• 30 Day Avg. Volume: 125,686
• PEG Ratio: 0.00
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $5.00 ▼(-3.66% Downside)

The score is primarily pressured by weak financial performance: ongoing pre-revenue losses, persistent negative cash flow, and major 2025 balance-sheet/cash-flow anomalies that raise uncertainty. Technicals also detract as the stock trades below major moving averages with negative MACD and weak RSI. Valuation provides limited offset given a negative P/E and no dividend yield.

Positive Factors

Regulatory Momentum

Securing breakthrough designation in Saudi Arabia could accelerate Multikine's path to commercialization, enhancing revenue prospects and global market presence.

Strategic Partnerships

Strategic partnerships in the Middle East could provide CEL-SCI with crucial support for Multikine's development and distribution, potentially boosting long-term growth and market access.

Product Development

Recognition of PD-L1 enhances Multikine's scientific credibility, potentially improving its acceptance and adoption in cancer treatment protocols, supporting long-term product success.

Negative Factors

Financial Instability

Ongoing financial instability, marked by negative cash flows and high debt, threatens CEL-SCI's ability to sustain operations without external financing, posing long-term viability risks.

Lack of Revenue

The absence of revenue generation highlights CEL-SCI's dependence on successful product commercialization, which remains uncertain, impacting financial sustainability.

Operational Losses

Persistent operational losses indicate inefficiencies and reliance on external funding, which could hinder long-term growth and strategic initiatives if not addressed.

Cel-Sci Business Overview & Revenue Model

Company Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

How the Company Makes Money

CEL-SCI Corporation primarily makes money through the development and potential commercialization of its lead product candidate, Multikine. The company aims to generate revenue from the eventual sale of Multikine, contingent upon successful clinical trials and regulatory approval. CEL-SCI may also seek revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships could involve sharing research, development costs, and profits from Multikine's commercialization. Additionally, CEL-SCI might receive funding through grants, investor funding, or other financing activities to support its research and development efforts.

Cel-Sci Financial Statement Overview

Summary

Cel-Sci is struggling financially, characterized by a lack of revenue generation, high operational losses, and dependency on external financing. The company's financial health is concerning, with persistent negative cash flows and significant debt levels posing risks to its sustainability.

Income Statement

Cel-Sci has consistently reported zero revenue over the past years, indicating a lack of product commercialization or sales. The gross profit and net income remain negative, reflecting ongoing operational losses and high costs relative to revenue. The company also faces negative EBIT and EBITDA margins, highlighting inefficiencies and challenges in achieving profitability.

Balance Sheet

The company's financial leverage is relatively high, as indicated by the debt-to-equity ratio, due to significant debt levels compared to equity. Stockholders' equity has been declining, with the equity ratio showing a downward trend. This reflects potential balance sheet risks, including financial instability and limited flexibility for future financing.

Cash Flow

Cel-Sci is experiencing negative operating and free cash flows, suggesting challenges in generating cash from operations. The company relies heavily on financing activities to fund operations, which may not be sustainable in the long term. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in cash generation relative to reported losses.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.89M	-3.89M	-3.97M	-3.96M	-3.88M	-499.00K
EBITDA	-20.88M	-20.88M	-22.21M	-27.56M	-31.74M	-34.71M
Net Income	-25.41M	-25.41M	-26.92M	―	-38.27M	-39.19M
Balance Sheet
Total Assets	28.16B	28.16B	26.99M	30.53M	50.52M	75.87M
Cash, Cash Equivalents and Short-Term Investments	10.95B	10.95B	4.74M	4.15M	22.67M	42.21M
Total Debt	9.38B	9.38B	11.62M	13.57M	15.30M	15.97M
Total Liabilities	12.20B	12.20B	14.12M	17.31M	18.36M	19.34M
Stockholders Equity	15.96M	15.96M	12.87M	13.21M	32.16M	56.53M
Cash Flow
Free Cash Flow	-17.16M	-17.16B	-18.91M	-23.22M	-18.90M	-27.83M
Operating Cash Flow	-17.12M	-17.12B	-18.81M	-22.85M	-18.24M	-18.79M
Investing Cash Flow	-38.11K	-38.11M	-108.09K	-372.26K	5.49M	-15.18M
Financing Cash Flow	23.37M	23.37B	19.51M	4.69M	-638.43K	54.52M

Cel-Sci Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVM, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 5.33, below the 50-day MA of 6.16, and below the 200-day MA of 6.77, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 41.44 is Neutral, neither overbought nor oversold. The STOCH value of 22.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVM.

Cel-Sci Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	58 Neutral	$110.79M	-1.53	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UNCY	49 Neutral	$126.15M	-1.86	-102.47%	―	―	66.05%
CVM	42 Neutral	$43.14M	-0.66	-176.32%	―	―	48.68%
PLRX	42 Neutral	$81.73M	-0.45	-64.27%	―	―	14.19%
ATHE	41 Neutral	$58.15M	-4.56	-42.68%	―	―	63.85%

Cel-Sci Corporate Events

Cel-Sci Extends Shareholder Rights Agreement to 2030

On October 30, 2025, CEL-SCI Corporation’s Board of Directors extended the expiration date of its Shareholder Rights Agreement to October 30, 2030. This amendment reflects the company’s ongoing efforts to manage shareholder interests and could impact its market positioning by providing stability and continuity for stakeholders.